Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth’s Pristiq Best-Case Launch Scenario Targets Menopause Market

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is re-inspecting the manufacturing facility cited in an “approvable” letter for Wyeth’s initial NDA for major depressive disorder.

You may also be interested in...



Wyeth Guayama Inspection Will Take Longer Than Anticipated

FDA’s inspection of the manufacturing facility is going to take “several more weeks,” firm announces.

Wyeth Guayama Inspection Will Take Longer Than Anticipated

FDA’s inspection of the manufacturing facility is going to take “several more weeks,” firm announces.

Wyeth’s Pristiq Deemed “Approvable” By FDA

Approval of Effexor XR follow-on is contingent upon inspection of firm's Puerto Rico manufacturing plant.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel